Investor
SUPERSTRING CAPITAL MANAGEMENT LP
CIK 0001931118 · filed 2026-05-14 · SEC filing
13F book
$140M
Positions
35
15 new · 25 sold
Largest name
12.1%
Summit Therapeutics Inc. · SMMT
Est. mark
−$824.2K
Price effect on 20 names still held. Flow −$46M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | SMMT | 892.9K | $16.9M | 12.1% | — | New |
| Immunovant, Inc. | IMVT | 357.6K | $8.88M | 6.3% | −$167.4K | Added$1.54M |
| Cogent Biosciences, Inc. | COGT | 225.2K | $8.67M | 6.2% | $668.7K | Cut−$4.34M |
| Savara Inc | SVRA | 1.59M | $8.66M | 6.2% | −$567.4K | Added$2.66M |
| UroGen Pharma Ltd. | URGN | 387.4K | $6.96M | 5.0% | −$2.11M | Cut−$9.86M |
| Definium Therape | DFTX | 351.5K | $6.64M | 4.7% | — | New |
| Vir Biotechnology, Inc. | VIR | 730.5K | $6.55M | 4.7% | — | New |
| Vaxcyte, Inc. | PCVX | 110.5K | $6.42M | 4.6% | — | New |
| Celldex Therapeutics Inc New | — | 180K | $5.71M | 4.1% | $402.7K | Added$3.31M |
| Sionna Therapeutics, Inc. | SION | 141K | $5.65M | 4.0% | −$148.1K | Cut−$1.78M |
| Genmab A/S | — | 196.7K | $5.28M | 3.8% | −$115.8K | Added$4.38M |
| Zai Lab Ltd | ZLAB | 275.8K | $5.19M | 3.7% | $230.3K | Added$1.72M |
| Vertex Pharmaceuticals Inc | — | 11K | $4.92M | 3.5% | — | New |
| Iqvia Hldgs Inc | — | 25.7K | $4.38M | 3.1% | — | New |
| MapLight Therapeutics, Inc. | MPLT | 192.1K | $3.91M | 2.8% | — | New |
| Arvinas, Inc. | ARVN | 312.6K | $3.31M | 2.4% | — | New |
| Oruka Therapeutics, Inc. | ORKA | 63.6K | $3.12M | 2.2% | — | New |
| United Therapeutics Corp Del | — | 5.19K | $3.08M | 2.2% | $548.3K | Cut−$1.53M |
| Travere Therapeutics, Inc. | TVTX | 102.8K | $3.05M | 2.2% | −$323.2K | Added$1.6M |
| Trevi Therapeutics, Inc. | TRVI | 251.6K | $3M | 2.1% | −$87.5K | Added$1.14M |
| Adlai Nortye Ltd. | ANL | 414.9K | $2.87M | 2.1% | — | New |
| Cabaletta Bio, Inc. | CABA | 1.07M | $2.87M | 2.0% | $533.1K | Cut−$2.07M |
| Pfizer Inc | PFE | 74K | $2.08M | 1.5% | — | New |
| Axsome Therapeutics, Inc. | AXSM | 11.2K | $1.9M | 1.4% | −$152.8K | Cut−$4.94M |
| Oric Pharmaceuticals, Inc. | ORIC | 115.2K | $1.46M | 1.0% | $517.4K | Cut−$628.9K |
| Aclaris Therapeutics, Inc. | ACRS | 366.5K | $1.37M | 1.0% | — | New |
| Climb Bio, Inc. | CLYM | 199.2K | $1.36M | 1.0% | — | New |
| Taysha Gene Therapies, Inc. | TSHA | 258.3K | $1.15M | 0.8% | −$266K | Cut−$4.24M |
| Bright Minds Biosciences Inc. | DRUG | 13.3K | $971.3K | 0.7% | −$67.5K | Cut−$2.72M |
| Tonix Pharmaceuticals Hldg C | — | 63.5K | $873.7K | 0.6% | — | New |
| Cullinan Therapeutics, Inc. | CGEM | 59.5K | $845.3K | 0.6% | — | New |
| Protara Therapeutics, Inc. | TARA | 121.5K | $632.8K | 0.5% | −$14.6K | Cut−$1.29M |
| Palatin Technologies Inc | PTN | 36K | $626.6K | 0.4% | $69.3K | Added$104.1K |
| Biomea Fusion, Inc. | BMEA | 250K | $382.5K | 0.3% | $72.5K | Held |
| Century Therapeutics, Inc. | IPSC | 119.3K | $269.6K | 0.2% | $150.9K | Cut−$190.9K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.